Business
Yeedozencom now has provided 300+ clinical trials and RA services for 100+ customers at home and abroad, and undergone strict quality audit and inspection. Meanwhile, we have rich experience in BE studies.
-
Clinical Trials
Clinical Research, Biological Analysis, SMO Services, Data Mgt. & Biost...
Learn more -
Regulatory Affairs
RA Service for Imported and Domestic Products, RA/Technology Consulting, R&...
Learn more -
Quality Assurance
Supplier Quality Audit, R&D Site Inspection, ManufacturingSite Inspecti...
Learn more -
Medical Affairs
protocl design and writing, medical support, medical monitoring, PV
Learn more -
DMPK/BA
Low-energy Radio-isotope Labeling Technology,QWBA,Drug Metabolite, MIST, Hu...
Learn more
News
-
2020-03-17Arbor Day | Make our earth more beautiful
Yeedozencom, a CRO service provider of full lifecycle technical services for pharmaceutical products, with in-depth and compassionate attitude!
-
2020-02-18Looking at Biomedical R&D trends from JPM Healthcare conference 2020
Innovative products / technologies will continue to be a key driver of focus in this area in 2020...
-
2020-02-09An Open Letter to Customers
We will maintain close communication with you, research institutions, suppliers by telephone, WeChat, email, and work together to mitigate the impact of the epidemic.
-
2020-02-07CDE Notice on Adjusting Drug Application Acceptance, Dossier Reception and Inquiry During Pneumonia Epidemic of Novel Coronavirus Infection
...
-
2020-01-17YEEDOZENCOM Appears at China Focus @ San Francisco 2020
The China Focus @ San Francisco 2020 was solemnly held in San Francisco, the United States on January 12, local time. As the largest China theme docking event in the JP Morgan Conference Week, this conference attracted more than 50 senior executives from well-known Chinese and foreign pharmaceutical companies and investment institutions, roadshows of 40 innovative companies and nearly 700 participants from China, the United States, Europe, Canada, Japan, South Korea and other countries.
-
2020-01-05YEEDOZENCOM Helped Qianjin Xieli to Pass the Consistency Evaluation of Generic Drugs of Entecavir Dispersible Tablets
Recently, Qianjin Xieli received "Drug Supplement Application Approval" of it's Entecavir Dispersible Tablets approved and issued by China NMDA. The product is deemed to have passed the Conformance Evaluation of the Quality and Efficacy of Generic Drugs.
